Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 288-293

  Mazzoni, Francesca ^a   Cecere, Fabiana Letizia ^a   Meoni, Giulia ^a   Giuliani, Costanza ^a   Boni, Luca ^b   Camerini, Andrea ^c   Lucchesi, Sara ^d   Martella, Francesca ^e   Amoroso, Domenico ^c   Lucherini, Elisa ^a   Torricelli, Francesca ^a   Di Costanzo, Francesco ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c Versilia Hospital   (Italy)

^d Pontedera Hospital   (Italy)

^e SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Chemotherapy; ERCC1; Non small cell lung cancer; Polymorphisms; RRM1; SNPs

Indexed keywords

CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; RIBONUCLEOTIDE REDUCTASE;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GENE; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RIBONUCLEOTIDE REDUCTASE M1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CHEMOTHERAPY; ERCC1; NON-SMALL-CELL LUNG CANCER; POLYMORPHISMS; RRM1; SNPS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84887023613     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.018     Document Type: Article

References (30)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
2. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46(4):765-781.
3. Kelly K., Crowley J., Bunn P.A. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-3218.
4. Schiller J.H., Harrington D., Belani C. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 2002, 346:92-98.
5. Scagliotti G.V., De Marinis F., Rinaldi M., Phase, et al. Randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
6. Fossella F., et al. Randomized multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX326 study group. J Clin Oncol 2003, 21:3016-3024.
7. Scagliotti G.V., Parikh P., von Pawel J., PhaseIII, et al. Study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
8. Scharer O.D. Chemistry and biology of DNA repair. Angew Chem Int Ed Engl 2003, 42(26):2946-2974.
9. Reed E., adduct Platinum-DNA. nucleotide excision repair and platinum-based anti-cancer chemotherapy. Cancer Treat Rev 1998, 24:331-344.
10. Wilson M.D., Ruttan C.C., Koop B.F., Glickman B.W. ERCC1: a comparative genomic perspective. Environ Mol Mutagen 2001, 38:209-215.
11. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
12. Cobo M., Isla D., Massuti B., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
13. Simon G., Sharma A., Li X., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25(19):2741-2746.
14. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New Engl J Med 2006, 355(10):983-991.
15. Reynolds C., Obasaju C., Schell M.J., et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27(34):5808-5815.
16. Ryu J.S., Hong Y.C., Han H.S., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44(3):311-316.
17. Isla D., Sarries C., Rosell R., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small cell lung cancer. Ann Oncol 2004, 15:1194-1203.
18. Su D. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007, 56(2):281-288.
19. Zhou W., Gurubhagavatula S., Liu G. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004, 10:4939-4943.
20. Takenaka T., Yano T., Kiyohara C., et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010, 67(1):101-117.
21. Davidson J.D., Ma L., Flagella M., et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64(11):3761-3766.
22. Rosell R., Danenberg K.D., Alberola V., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004, 10:1318-1325.
23. Bepler G., Kusmartseva I., Sharma S., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24:4731-4737.
24. De Las Penas R., Sanchez-Ronco M., Alberala V., et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006, 17(4):668-675.
25. Kim S.O., Jeong J.Y., Kim M.R., et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008, 14:3083-3088.
26. Dong S., Guo A.L., Chen Z.H., et al. RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J Hematol Oncol 2010, 3(1):10.
27. Bepler G., Williams C., Schell M.J., et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2013, 31:2404-2412.
28. Zhou C., Ren S., Zhou S., et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. J Clin Oncol 2010, 40(10):954-960.
29. Li F., Sun X., Sun N., Qin S., et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 2010, 33(5):489-494.
30. Pierceall W.E., Olaussen K.A., Rousseau V., et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclass. Ann Oncol 2012, 23:2245-2252.